Redwood AI and UBC Collaborate on Alzheimer's Drug Research

Redwood AI Corp has initiated a collaborative project with the Brent Page Lab at the University of British Columbia, focusing on Alzheimer's drug discovery. The initiative targets the protein NUDT5, associated with neurodegeneration in Alzheimer's. Using AI-driven computational research, Redwood aims to design and optimize inhibitors that could expedite the drug discovery process.

The project seeks to generate virtual libraries of compounds for evaluation and subsequently guide the experimental efforts of the Page Lab. This approach merges artificial intelligence with medicinal chemistry and biological testing, potentially accelerating the path to preclinical development.

Louis Dron, CEO of Redwood AI, highlighted the role of AI in transforming drug discovery, aiming to streamline the transition from discovery to stronger preclinical candidates. The collaboration hints at a promising shift toward faster therapeutic innovation.